Increased osteopontin protein expression may be correlated with poor prognosis in non-small-cell lung cancer: A meta analysis

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 1, 2016, Pages 277-282

  Shi, Shao Min ^a   Su, Zhen Bo ^a   Zhao, Jian Jun ^a   Yu, Du Juan ^a   Tu, Jun Wei ^b   Zhu, Jing ^b   Zhao, Jian Ping ^b   Sheng, Lin ^b   Wang, Sai Bin ^b   Sheng, Yi Jun ^b   Chen, Hui Jun ^b   Tian, Jiang Hua ^b   Zhang, Yi ^b   Wang, Jing ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b Jinhua Central Hospital   (China)

Author keywords

Meta analysis; non small cell lung cancer; osteopontin; prognosis

Indexed keywords

OSTEOPONTIN; TUMOR MARKER;

ARTICLE; ASIAN; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; PATHOLOGY; PROGNOSIS; PROTEOMICS; SURVIVAL ANALYSIS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOPONTIN; PROGNOSIS; PROTEOMICS; SURVIVAL ANALYSIS;

EID: 84966642081     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.150362     Document Type: Article

References (38)

1. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al., NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
2. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al., NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. J Natl Compr Canc Netw 2012;10:1236-71.
3. Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, et al. Overexpression of osteopontin, ανβ 3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS One 2012;7:e48575.
4. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004. J Thorac Oncol 2009;4:1104-10.
5. Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, et al. Expressions of Osteopontin (OPN), ανβ3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC). Chin J Cancer Res 2012;24:103-8.
6. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
8. Blumenschein GR Jr, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, et al. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study. J Thorac Oncol 2012;7:1406-16.
9. Takenaka M, Hanagiri T, Shinohara S, Yasuda M, Chikaishi Y, Oka S, et al. Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer 2013;14:288-94.
10. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Thorac Oncol 2010;5:1516-23.
11. Singh M, Foster CR, Dalal S, Singh K. Osteopontin: Role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol 2010;48:538-43.
12. Weber CE, Li NY, Wai PY, Kuo PC. Epithelial-mesenchymal transition, TGF-β, and osteopontin in wound healing and tissue remodeling after injury. J Burn Care Res 2012;33:311-8.
13. Matusan-Ilijas K, Damante G, Fabbro D, Dordevic G, Hadzisejdic I, Grahovac M, et al. Osteopontin expression correlates with nuclear factor-kB activation and apoptosis downregulation in clear cell renal cell carcinoma. Pathol Res Pract 2011;207:104-10.
14. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res 2011;49:160-72.
15. Baliga SS, Merrill GF, Shinohara ML, Denhardt DT. Osteopontin expression during early cerebral ischemia-reperfusion in rats: Enhanced expression in the right cortex is suppressed by acetaminophen. PLoS One 2011;6:e14568.
16. Murugaiyan G, Mittal A, Weiner HL. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A 2010;107:11495-500.
17. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 2011;32:477-87.
18. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21:1401-9.
19. Kohan M, Breuer R, Berkman N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am J Respir Cell Mol Biol 2009;41:290-6.
20. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009;17:153-61.
21. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, et al. Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 2011;9:280-93.
22. Dahiya S, Givvimani S, Bhatnagar S, Qipshidze N, Tyagi SC, Kumar A. Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol 2011;187:2723-31.
23. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010;28:936-41.
24. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006;6:819-30.
25. Boldrini L, Donati V, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, et al. Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 2005;93:453-7.
26. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26:4771-6.
27. Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY, Park S, et al. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2013;75:104-10.
28. Ostheimer C, Bache M, Guttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol 2014;190:276-82.
29. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
30. Zintzaras E, Ioannidis JP. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 2005;21:3672-3.
31. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-80.
32. Cui LP, Zhang J, Yin M, H. C. Relationship between serum steopontin levels and prognosis in non-small cell lung cancer. J Ningxia Med Univ 2012;34:248-51,56.
33. Wu J, Zhang C, Zhu YN. The expression and its clinical significance of opn and MMP-2 in non-small cell lung cancer. Chin J Clin Exp Pathol 2012;28:924-6.
34. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK, et al. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 2013;13:540.
35. Sun BS, Li Y, Zhang ZF, You J, Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 2013;96:1943-51.
36. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep 2011;25:433-41.
37. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, et al. Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 2011;137:1061-70.
38. Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol 2010;148:235-44.